For research use only. Not for therapeutic Use.
CC-930（Cat No.:I005384）is an investigational small molecule that acts as a selective inhibitor of the enzyme Janus kinase 1 (JAK1). JAK1 is a key regulator of the immune response and inflammation, making CC-930 a promising candidate for treating autoimmune diseases, inflammatory disorders, and certain cancers. By inhibiting JAK1, CC-930 can modulate cytokine signaling and reduce pathological inflammation. Early-stage clinical trials have suggested its potential in treating conditions like rheumatoid arthritis and psoriasis. However, further research is needed to assess its safety, efficacy, and long-term effects in diverse patient populations.
| Catalog Number | I005384 |
| CAS Number | 899805-25-5 |
| Synonyms | 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol |
| Molecular Formula | C21H23F3N6O2 |
| Purity | ≥95% |
| Target | JNK |
| Solubility | DMSO: ≥ 33 mg/mL |
| Storage | Store at -20°C |
| IC50 | 61 nM (JNK1); 7 nM (JNK2); 6 nM (JNK3) [1] |
| IUPAC Name | 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol |
| InChI | InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1 |
| InChIKey | IBGLGMOPHJQDJB-MOKVOYLWSA-N |
| SMILES | C1COC[C@H]1N2C3=NC(=NC=C3N=C2NC4=C(C=C(C=C4F)F)F)NC5CCC(CC5)O |
| Reference | 1:Bioorg Med Chem Lett. 2012 Feb 1;22(3):1433-8. doi: 10.1016/j.bmcl.2011.12.027. Epub 2011 Dec 10. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.Plantevin Krenitsky V,Nadolny L,Delgado M,Ayala L,Clareen SS,Hilgraf R,Albers R,Hegde S,D/’Sidocky N,Sapienza J,Wright J,McCarrick M,Bahmanyar S,Chamberlain P,Delker SL,Muir J,Giegel D,Xu L,Celeridad M,Lachowitzer J,Bennett B,Moghaddam M,Khatsenko O,Katz J,Fan R,Bai A,Tang Y,Shirley MA,Benish B,Bodine T,Blease K,Raymon H,Cathers BE,Satoh Y, PMID: 22244937 DOI: 10.1016/j.bmcl.2011.12.027 </br><span>Abstract:</span> In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors. Improving the physico-chemical properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors. Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 1 (CC-930) as a development candidate, which is currently in Phase II clinical trial for IPF.Copyright © 2011 Elsevier Ltd. All rights reserved. |
